Anti-PD-1 mAbs treatments cause proliferation of PD-1+ Treg cells in some gastric cancer patients, thereby increasing Treg cell-mediated immunosuppressive activity and promoting disease hyper-progression during PD-1 blockade therapy [99]. The gene discussed is PDCD1; the disease is gastric cancer.